Pure Global AI
NCT06395935Recruiting

Wecare Study in Gastric Cancer Survivors

A Multi-center, Prospective, Randomized Study to Evaluate the Usefulness of Applying the Chronic Side Effect Management Platform (Wecare) in Gastric Cancer Survivors
Gyeongsang National University HospitalClinicalTrials.govother
Verified
Study focus
Disease/Condition
Gastric Cancer
Drug/Device/Intervention
Wecare (website)
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Gyeongsang National University Hospital
Location
Changwon, South Korea
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2024
End date
Mar 30, 2026
Enrollment
88 participants
Primary outcome

the quality of life in gastric cancer survivor (KOQUSS-40)

Summary

The KOrean QUality of life in Stomach cancer patients Study group (KOQUSS) made a method
 (KOQUSS-40) for assessing appropriately the quality of life of gastric cancer patients who
 have undergone gastrectomy, and developed a digital platform (Wecare) based on KOQUSS-40. In
 this study, we propose a randomized controlled trial to compare quality of life after
 gastrectomy in patients with and without smartphone app support.

ICD-10 classifications
Gastric ulcerMalignant neoplasm of stomachMalignant neoplasm: Body of stomachCarcinoma in situ: StomachMalignant neoplasm: Stomach, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06395935
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06395935 through Pure Global AI's free database. This phase not specified trial is sponsored by Gyeongsang National University Hospital and is currently Recruiting. The study focuses on Gastric Cancer. Target enrollment is 88 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.